Menu

Conferences

MedEU Bios Med High

Medicines for Europe 20th Biosimilar Medicines Conference 2024

Home/Conferences | Posted 22/03/2024

20th Biosimilar Medicines Conference
18–19 April 2024
Hilton Amsterdam Schiphol
The Netherlands

MedEU logo V23D20LT

Medicines for Europe 18th Legal Affairs Conference 2024

Home/Conferences | Posted 22/03/2024

18th Legal Affairs Conference
10–11 June 2024
Portmarnock Hotel & Golf Links
Dublin
Ireland

MedEU logo V23D20LT

Medicines for Europe 29th Annual Conference 2024

Home/Conferences | Posted 22/03/2024

29th ANNUAL CONFERENCE
12–13 June 2024
Portmarnock Hotel & Golf Links
Dublin
Ireland

ASBM 2023 Webinar IC V23L05 replay

ASBM/GaBI 2023 webinar on INTERCHANGEABILITY DESIGNATION FOR BIOSIMILARS

Home/Conferences | Posted 12/12/2023

ASBM/GaBI 2023 webinar on Interchangeability Designation for Biosimilars

INTERCHANGEABILITY DESIGNATION FOR BIOSIMILARS
Ensuring Continuity of Patient Care: Upholding Interchangeability Status for Biosimilars
30 November 2023 | WATCH REPLAY

ASBM 2023 Webinar IRA BG V23H11 replay

ASBM/GaBI 2023 webinar on MEDICARE DRUG PRICE NEGOTIATIONS

Home/Conferences | Posted 14/07/2023

ASBM/GaBI 2023 Webinar on Inflation Reduction Act

MEDICARE DRUG PRICE NEGOTIATIONS:
impact on healthcare development and patient access to medicines
26 July 2023 | WATCH REPLAY

ASBM 2022 Webinar 2 Banner Square V22G29 replay

ASBM/GaBI 2022 biosimilar webinar on non-medical switching

Home/Conferences | Posted 03/06/2022

ASBM/GaBI Biosimilar Webinar 2022

NON-MEDICAL SWITCHING OF BIOLOGICALS/BIOSIMILARS: CANADA, EUROPE AND THE US
Overview of Non-Medical Switching Practices in Different Regions and the Importance of Safeguarding the Physician–Patient Relationship

20 July 2022 | WATCH REPLAY

ASBM 2022 Webinar 1 Banner Square V22G25LT replay

ASBM/GaBI 2022 biosimilar webinar on biosimilars uptake

Home/Conferences | Posted 26/08/2022

ASBM/GaBI Biosimilar Webinar 2022

KEY FACTORS FOR SUCCESSFUL UPTAKE OF BIOSIMILARS: EUROPE AND THE US
Measures taken for improving biosimilar uptake and the potential role of healthcare providers and patients

29 June 2022 | WATCH REPLAY

GW 5017K Kurki

Pekka Kurki receives Van der Does Award

Home/Conferences | Posted 20/06/2023

The 2023 Van der Does Award for rational and cost-effective drug treatment was presented to Dr Pekka Kurki at the Medicines for Europe Conference 2023, Amsterdam, The Netherlands.

DIA logo V23D20LT

DIA Europe 2023 – a brief report

Home/Conferences | Posted 20/04/2023

The 35th edition of DIA Europe, the largest neutral forum for healthcare stakeholders in Europe, concluded on 24 March 2023 with resounding success. The three-day congress took place in Basel, Switzerland and attracted over 1,700 attendees from across the globe, making it a must-attend for the life sciences industry.

149 AA010954

Microbiological control symposium: consensus on readiness of new methods emerges

Home/Conferences | Posted 27/10/2017

A symposium on microbiology in the pharmaceutical sector was the opportunity for the European Directorate for the Quality of Medicines & HealthCare (EDQM) to gather feedback from users of the European Pharmacopoeia on alternative testing methods for microbiological control and sterilisation processes. The event, which took place in Strasbourg on 10−11 October 2017, was attended by a wide range of experts in the pharmaceutical and microbiological fields who reviewed the latest trends and innovations in the field of microbiology, in addition to pharmacopoeial approaches and related regulatory requirements.

10 AA008993

European Pharmacopoeia prepares for the future through exchange with stakeholders

Home/Conferences | Posted 14/10/2016

To mark the publication of the 9th edition of the European Pharmacopoeia (Ph. Eur.), the EDQM (European Directorate for the Quality of Medicines) organized a large international conference in Tallinn, Estonia, which brought together representatives of European and international regulatory authorities, the World Health Organization (WHO), pharmacopoeias from different continents as well as industry and associations from Europe and beyond. Participants came from 41 different countries, including Brazil, Canada, India, Japan, South Africa, Taiwan and USA.

Meeting V13F14

Extrapolation key issue at European biosimilars conference

Home/Conferences | Posted 25/09/2015

The European Generic medicines Association (EGA) held its 13th EGA-European Biosimilars Group Conference in London on 23–24 April 2015.

02 AA010638

French generics association promotes biosimilars

Home/Conferences | Posted 17/10/2014

French generics association GEMME held its first symposium on the challenges and opportunities associated with biosimilars in France on 3 October 2014.

Conference V14A17

Topics presented at the 16th IGPA conference on generics

Home/Conferences | Posted 17/01/2014

Topics presented at the 16th Annual IGPA Conference, held in Brussels, Belgium, 9–11 December 2013, showed that despite differences in the pharmaceutical market in different countries most appreciate the value of generics. In most cases this is driven by cost reduction.

picture 79

EGA pushes for increased focus on generics and biosimilars

Home/Conferences | Posted 21/06/2013

EGA President Ms Gudbjorg Edda Eggertsdottir, speaking at the European Generic medicines Association’s (EGA’s) conferences in London, UK (11th EGA International Symposium on Biosimilar Medicines) and in Athens, Greece (19th EGA Annual Conference); stressed the importance of keeping generics and biosimilars manufacturers within Europe, thus ensuring that high quality manufacturing jobs and know-how remains in Europe. This would benefit society and patients and increase the competitiveness and innovative capacity of the pharmaceutical industry in Europe.

GW 1340K dia-25-eurom-143 V13c21

Report on 25th Annual EuroMeeting, 4-6 March 2013, Amsterdam, The Netherlands

Home/Conferences | Posted 05/04/2013

Delegates at DIA’s 25th Anniversary of the EuroMeeting, held on 4–6 March 2013 in Amsterdam, The Netherlands, were offered the mouth watering prospect of more than 100 sessions across 17 themes, addressed by 300+ Speakers from EMA, European Commission, FDA and other national regulatory agencies. Most popular sessions included Implementation of the New Pharmacovigilance Legislation, the Regulatory Town Hall Meeting and the sell-out European Landscape on HTA - the EUnetHTA Joint Action. Eighteen pre-conference tutorials were led by an expert faculty and 120 students, young professional and patients all attended sessions created especially for them.

Patient power predominates at DIA Europe’s Clinical Forum

Home/Conferences | Posted 17/08/2012

DIA Europe’s 2012 Clinical Forum in October this year promises to be an important multidisciplinary conference for all engaged in the clinical development and therapeutic use of medicines. The theme for 2012 is ‘The Empowered Patient’, an acknowledgement of the inescapable fact that the evolution of technology and electronic communication has given patients the ability to find and share health information which will impact their treatment choices – empowering them to become more engaged in their care and to participate in decisions about it.

picture 83

Need for global development programme for biosimilars

Home/Conferences | Posted 04/05/2012

There is now a crucial need for a framework that allows global biosimilars development.

picture 72

Removal of barriers for the global development of biosimilars

Home/Conferences | Posted 23/04/2012

At the 2012 Biosimilars Medicines: 10th EGA International Symposium, held in London, UK, on 19–20 April 2012; Mr Nils Behrndt (Deputy Head of Cabinet DG Sanco, European Commission) announced that the European Commission (EC) wishes to stimulate the global development of biosimilars. The EC has thereby two objectives:

picture 70

European Commission calls for wider use of generic medicines

Home/Conferences | Posted 23/04/2012

At the 10th International Symposium on Biosimilar Medicines, organised by the European Generics medicines Association, held in London, UK, on 19–20 April 2012; the European Commission (EC) highlighted the need to stimulate wider use of generic medicines.